PRF Technologies has signed a term sheet with Dotz Nano for a strategic collaboration to commercialize and expand the GridFeed AI platform, which optimizes renewable energy forecasting, battery storage, and electricity trading. Dotz will acquire GridFeed for $1 million and launch it under an exclusive license, while PRF will take an equity stake in Dotz. This partnership combines Dotz's energy consumption optimization with PRF's supply-side AI technology, aiming to offer a comprehensive energy management solution. The deal supports PRF's focus on healthcare innovations by providing capital and market reach through Dotz's commercialization capabilities.
PRF Technologies and Dotz Nano's strategic collaboration on AI-driven energy optimization comes as 27 of 79 Energy-sector US stocks on Pluang rose while 51 fell. As of Nov 04, 2026 04:21 WIB, notable movers include Enphase Energy Inc (ENPH) with a price of USD 30.52 and a 9.27% increase, Solaredge Technologies Inc (SEDG) at USD 32.52 with a 7.66% rise, and SM Energy Company Common Stock (SM) dropping 8.33% to USD 34.32. Typical hold times and order activity vary, with ENPH held for 72 days and 78% buy orders, while SM and SEDG show 100% sell orders.
Nova Klúbburinn hf. has completed a share buyback program, acquiring 122,699,386 shares at an average price of ISK 3.26 per share. The buyback was part of an inverse offer process with valid bids for 159,526,476 shares. The company accepted bids up t...
AMC Entertainment will release its Q3 2026 earnings on Nov. 4, following a year-over-year increase in North American box-office receipts to about $3.1 billion from $2.5 billion in Q3 2025. The quarter featured major film releases like Spider-Man: Bra...
Pomerantz LLP is investigating Erasca, Inc. following the termination of its COO, Nicholas Chetwyn, which led to a nearly 10% drop in the company's stock price. The investigation focuses on whether Erasca and its executives engaged in securities frau...
Pomerantz LLP is investigating claims against Yiren Digital Ltd. for possible securities fraud following the company's disclosure of a 34% revenue decline and a significant net loss in Q4 2025. The company also reported increased delinquency rates an...
Pomerantz LLP is investigating Syndax Pharmaceuticals following the company's announcement that its Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint. This news caused Syndax's stock to drop by 2.59% on...
